Alex Aravanis

876 total citations
16 papers, 186 citations indexed

About

Alex Aravanis is a scholar working on Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alex Aravanis has authored 16 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cancer Research, 9 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alex Aravanis's work include Cancer Genomics and Diagnostics (16 papers), Genetic factors in colorectal cancer (5 papers) and Molecular Biology Techniques and Applications (5 papers). Alex Aravanis is often cited by papers focused on Cancer Genomics and Diagnostics (16 papers), Genetic factors in colorectal cancer (5 papers) and Molecular Biology Techniques and Applications (5 papers). Alex Aravanis collaborates with scholars based in United States and United Kingdom. Alex Aravanis's co-authors include Oliver Venn, Tara Maddala, Anne‐Renee Hartman, Earl Hubbell, Arash Jamshidi, Samuel Gross, Minetta C. Liu, Ling Shen, Darya Filippova and Richard T. Williams and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Global Oncology.

In The Last Decade

Alex Aravanis

16 papers receiving 183 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alex Aravanis United States	7	159	93	81	70	47	16	186
Alexander M. Frankell United Kingdom	6	109 0.7×	84 0.9×	85 1.0×	64 0.9×	47 1.0×	7	221
Anja Lisa Riediger Germany	6	215 1.4×	126 1.4×	84 1.0×	125 1.8×	43 0.9×	9	259
E. Ococks United Kingdom	3	84 0.5×	82 0.9×	76 0.9×	54 0.8×	40 0.9×	3	198
Sujath Abbas United Kingdom	4	70 0.4×	79 0.8×	66 0.8×	71 1.0×	38 0.8×	4	218
Stephen Cristiano United States	7	111 0.7×	61 0.7×	43 0.5×	55 0.8×	35 0.7×	11	157
Justin Burgener Canada	5	169 1.1×	64 0.7×	59 0.7×	148 2.1×	19 0.4×	8	222
Cleo Keppens Belgium	10	174 1.1×	86 0.9×	102 1.3×	88 1.3×	65 1.4×	25	243
Zhihong Zhang China	7	93 0.6×	73 0.8×	63 0.8×	61 0.9×	32 0.7×	22	165
Juliane Perner United Kingdom	9	73 0.5×	84 0.9×	72 0.9×	142 2.0×	29 0.6×	12	282
Maggie Banys‐Paluchowski Germany	8	143 0.9×	40 0.4×	116 1.4×	39 0.6×	50 1.1×	46	205

Countries citing papers authored by Alex Aravanis

Since Specialization

Citations

This map shows the geographic impact of Alex Aravanis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Aravanis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Aravanis more than expected).

Fields of papers citing papers by Alex Aravanis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Aravanis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Aravanis. The network helps show where Alex Aravanis may publish in the future.

Co-authorship network of co-authors of Alex Aravanis

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Aravanis. A scholar is included among the top collaborators of Alex Aravanis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Aravanis. Alex Aravanis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Wolpin, Brian M., Donald Richards, Allen Lee Cohn, et al.. (2020). Performance of a blood-based test for the detection of multiple cancer types.. Journal of Clinical Oncology. 38(4_suppl). 283–283. 1 indexed citations

2.

Bredno, Joerg, Jafi A. Lipson, Oliver Venn, et al.. (2020). Tumor area and microscopic extent of invasion to determine circulating tumor DNA fraction in plasma and detectability of colorectal cancer (CRC).. Journal of Clinical Oncology. 38(4_suppl). 243–243. 4 indexed citations

3.

Hubbell, Earl, Tara Maddala, Oliver Venn, et al.. (2019). Abstract 3372: Cell-free DNA (cfDNA) fragment length patterns of tumor- and blood-derived variants in participants with and without cancer. 3372–3372. 1 indexed citations

4.

Hubbell, Earl, Tara Maddala, Oliver Venn, et al.. (2019). Abstract 3372: Cell-free DNA (cfDNA) fragment length patterns of tumor- and blood-derived variants in participants with and without cancer. Cancer Research. 79(13_Supplement). 3372–3372. 1 indexed citations

5.

Oxnard, Geoffrey R., Xiaoji Chen, Eric T. Fung, et al.. (2019). Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis.. Journal of Clinical Oncology. 37(15_suppl). 1545–1545. 6 indexed citations

6.

Filippova, Darya, Matthew H. Larson, M. Cyrus Maher, et al.. (2019). The Circulating Cell-free Genome Atlas (CCGA) Study: Size selection of cell-free DNA (cfDNA) fragments.. Journal of Clinical Oncology. 37(15_suppl). 3103–3103. 2 indexed citations

7.

Liu, Minetta C., Arash Jamshidi, Oliver Venn, et al.. (2019). Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.. Journal of Clinical Oncology. 37(15_suppl). 3049–3049. 16 indexed citations

8.

Oxnard, Geoffrey R., Eric A. Klein, Michael V. Seiden, et al.. (2019). Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA).. Journal of Global Oncology. 5(suppl). 44–44. 14 indexed citations

9.

Swanton, Charles, Oliver Venn, Alex Aravanis, et al.. (2018). Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.. Journal of Clinical Oncology. 36(15_suppl). 12003–12003. 35 indexed citations

10.

Liu, Minetta C., Tara Maddala, Alex Aravanis, et al.. (2018). Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.. Journal of Clinical Oncology. 36(15_suppl). 536–536. 20 indexed citations

11.

Klein, Eric A., Earl Hubbell, Tara Maddala, et al.. (2018). Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.. Journal of Clinical Oncology. 36(15_suppl). 12021–12021. 38 indexed citations

12.

Oxnard, Geoffrey R., Tara Maddala, Earl Hubbell, et al.. (2018). Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.. Journal of Clinical Oncology. 36(18_suppl). LBA8501–LBA8501. 18 indexed citations

13.

Razavi, Pedram, Bob T. Li, Wassim Abida, et al.. (2017). Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer.. Journal of Clinical Oncology. 35(18_suppl). LBA11516–LBA11516. 6 indexed citations

14.

Razavi, Pedram, Bob T. Li, Wassim Abida, et al.. (2017). Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer.. Journal of Clinical Oncology. 35(15_suppl). LBA11516–LBA11516. 3 indexed citations

15.

Razavi, Pedram, Bob T. Li, Chenlu Hou, et al.. (2017). Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: Implications for interpretation of liquid biopsy tests.. Journal of Clinical Oncology. 35(15_suppl). 11526–11526. 20 indexed citations

16.

Li, Bob T., Filip Jankú, Pasi A. Jänne, et al.. (2016). Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium. Cancer Research. 76(14_Supplement). 4342–4342. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact